We are developing new treatment options to help patients with rare metabolic disorders.
Azafaros was founded in 2018 by a team of experienced industry professionals and scientists aspiring to address rare genetic metabolic disorders through a pipeline of oral small molecules with disease-modifying potential. Based on discoveries from Leiden University and Amsterdam UMC, Azafaros’s proprietary lead compound AZ-3102 will initially address inherited life-threatening lysosomal storage diseases for which there are no effective therapies today.
This orally available azasugar compound interferes with the metabolism of glycolipids and uniquely affects several key disease pathways through a dual mode of action. Leveraging the know-how of its team and partners in orphan drug development, the company is advancing its lead program toward first-in-man studies while further expanding its product pipeline into other rare metabolic diseases through its drug discovery efforts.
Azafaros was founded in 2018 by a team of experienced industry professionals and scientists aspiring to address rare genetic metabolic disorders through a pipeline of oral small molecules with disease-modifying potential. Based on discoveries from Leiden University and Amsterdam UMC, Azafaros’s proprietary lead compound AZ-3102 will initially address inherited life-threatening lysosomal storage diseases for which there are no effective therapies today.
This orally available azasugar compound interferes with the metabolism of glycolipids and uniquely affects several key disease pathways through a dual mode of action. Leveraging the know-how of its team and partners in orphan drug development, the company is advancing its lead program toward first-in-man studies while further expanding its product pipeline into other rare metabolic diseases through its drug discovery efforts.
Location: Netherlands
Employees: 1-10
Total raised: $175.64M
Investors 3
| Date | Name | Website |
| 10.06.2025 | Jeito Capi... | jeito.life |
| - | BioGenerat... | biogenerat... |
| - | Forbion | forbion.co... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 11.09.2025 | Series B | $611.07M | - |
| 13.05.2025 | Series B | $147.64M | Forbion |
| 18.02.2020 | Series A | $28M | - |
Mentions in press and media 22
| Date | Title | Description |
| 07.05.2026 | Healthtech: 10 companies that raised the most in 2025 | In 2025, Europe’s healthtech ecosystem showed strong funding momentum, with capital concentrated in large rounds across biotech, medtech, digital health, and AI-enabled healthcare. The biggest deals came from companies such as Oura Health, ... |
| 18.09.2025 | Capital meets care: 10 venture capital firms transforming healthcare across Europe | Venture capital remains one of the cornerstones of Europe’s innovation landscape, fuelling the growth of startups across every sector. In our last list, we spotlighted 15 VC firms focused on sustainability, underlining how investors are sha... |
| 15.09.2025 | Europe's VC Shift: UK Fights for Lead as Healthtech Soars in 2025 | European venture capital is undergoing significant shifts in 2025. The UK remains a leader, but emerging competition from Germany and France is notable. Healthtech and AI innovation are major investment drivers, securing billions across the... |
| 11.09.2025 | Europe's 10 biggest healthtech deals in H1 2025 | Healthtech continued to demonstrate its strength in Europe in the first half of 2025, attracting €4 billion in funding, around 12 per cent of the €33.7 billion raised across all European tech sectors. Although healthtech accounted for just ... |
| 08.08.2025 | Swiss VC investment in H1 reflects global trends | The market research and analytics firm CB Insights recently published its quarterly State of Venture report, analyzing startup ecosystem developments across the globe. A comparison with the H1 Update of the Swiss Venture Capital Report rev... |
| 10.06.2025 | May 2025's top 10 European tech deals you need to know about | In May, European tech companies raised a total of €5.5 billion across 341 deals, a 66.7% increase from April’s €3.3 billion and 311 deals. Despite the month-on-month growth, the figure remains 48% lower than May 2024, reflecting ongoing inv... |
| 19.05.2025 | Azafaros: €132 Million Secured To Develop Treatments For Lysosomal Storage Disorders | Azafaros, a clinical-stage company focused on developing disease-modifying therapeutics to offer new treatment options to patients with rare lysosomal storage disorders, announced the completion of an oversubscribed €132 million Series B fi... |
| 16.05.2025 | Anthropic's met monthly with UK tech secretary, Wave Ventures triples fund size, and Gnosis acquires HQ.xyz for $15M | This week we tracked more than 75 tech funding deals worth over €909 million, and over 15 exits, M&A transactions, rumours, and related news stories across Europe. If email is more your thing, you can always subscribe to our newsletter ... |
| 14.05.2025 | The Rise of Biotech: A New Era of Innovation and Investment | In the world of biotechnology, the stakes are high and the rewards can be life-changing. Recent funding rounds reveal a landscape ripe with potential. Companies like Azafaros and Eligo Bioscience are leading the charge, armed with innovativ... |
| 13.05.2025 | Eligo Bioscience Secures $5M Grant | Eligo Bioscience, a Paris, France-based biotechnology company pioneering the development of novel genetic medicines, received a $5M grant from the French government. The funding is part of the call for proposals “Innovations in Biotherapies... |
Show more